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Abstract
Background: Both recurrent and population specific mutations have been found in different areas
of the world and more specifically in ethnically defined or isolated populations. The population of
Slovenia has over several centuries undergone limited mixing with surrounding populations.
The current study was aimed at establishing the mutation spectrum of BRCA1/2 in the Slovenian
breast/ovarian cancer families taking advantage of a complete cancer registration database. A
second objective was to determine the cancer phenotype of these families.
Methods: The original population database was composed of cancer patients from the Institute of
Oncology Ljubljana in Slovenia which also includes current follow-up status on these patients. The
inclusion criteria for the BRCA1/2 screening were: (i) probands with at least two first degree
relatives with breast and ovarian cancer; (ii) probands with only two first degree relatives of breast
cancer where one must be diagnosed less than 50 years of age; and (iii) individual patients with
breast and ovarian cancer, bilateral breast cancer, breast cancer diagnosed before the age of 40 and
male breast cancer without any other cancer in the family.
Results: Probands from 150 different families met the inclusion criteria for mutation analysis of
which 145 consented to testing. A BRCA1/2 mutation was found in 56 (39%). Two novel large
deletions covering consecutive exons of BRCA1  were found. Five highly recurrent specific
mutations were identified (1806C>T, 300T>G, 300T>A, 5382insC in the BRCA1 gene and IVS16-
2A>G in the BRCA2 gene). The IVS16-2A>G in the BRCA2 gene appears to be a unique founder
mutation in the Slovenian population. A practical implication is that only 4 PCR fragments can be
used in a first screen and reveal the cancer predisposing mutation in 67% of the BRCA1/2 positive
families. We also observed an exceptionally high frequency of 4 different pathogenic missense
mutations, all affecting one of the cryptic cysteine residues of the BRCA1 Ring Finger domain.
Conclusion: A high mutation detection rate and the frequent occurrence of a limited array of
recurring mutations facilitate BRCA1/2 mutation screening in Slovenian families.
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Background
Breast cancer is the most common malignancy among
women in developed countries. A family history of breast
and/or ovarian cancer is the most important risk factor for
the development of these cancers [1]. It is estimated that
about 5 – 10% of breast cancer cases may be due to inher-
ited predisposition [2]. In the context of high risk families
studies have provided the evidence for at least two major
cancer susceptibility genes: BRCA1  (17q21) [3] and
BRCA2 (13q12) [4]. The cumulative risk for breast cancer
for a woman carrying a BRCA1 or BRCA2 mutation is esti-
mated to be as high as 85% by the age of 70 years and
female carriers are also at a substantially increased risk of
developing ovarian cancer [5].
Since the initial identification of both genes more than
3700 cancer predisposing mutations have been reported
to the Breast Cancer Information Core (BIC) [6]. So far,
most mutations have been identified in a single or a few
families at most. However, several founder mutations are
described in defined populations, such as the Ashkenazi
Jewish [7], the Icelandic [8] and the Dutch population [9].
We have previously reported a highly recurrent BRCA2
founder mutation for the Slovene population [10]. Slove-
nia has two million inhabitants and every year close to
1100 women are diagnosed with breast cancer [11].
Genetic counselling for inherited breast/ovarian cancer in
Slovenia started at the Institute of Oncology Ljubljana,
Slovenia in October 1999. Until then the interest of Slov-
enian population (and health care workers) in cancer
genetic counselling was unknown. The first step in imple-
menting a BRCA1/2  genetic counselling program that
includes mutation screening and then carrier detection in
families found mutation-positive, was the approval of the
Commission for Medical Ethics at the Ministry of Health,
Republic of Slovenia.
The aim of our study was to assess: (i) the nature of
BRCA1/2 mutations found in Slovenian population and
(ii) the cancer phenotype in BRCA1/2 mutation positive
families.
For anticipated cost-effectiveness issues, a mutation
screen was only initiated in families that met minimal
inclusion criteria with regard to cancer phenotype as
detailed below [12].
Methods
Patients and families
This study was performed with families residing in Slove-
nia, and more specifically those followed at the Institute
of Oncology of Ljubljana; the major centralized cancer
centre in the country responsible for the national cancer
registry. The accrual period was from October 1999
through March 2006. Cancer patients who were under
surveillance at the Institute received a document with
written information on familial cancer and a form in
which they could detail the cancer diagnoses in the family.
The questionnaire asked for detailed information in order
to gather the required information about the cancer diag-
noses and age of cancer incidence. This information was
in addition cross – checked in the comprehensive data-
base of the population cancer registry of the Institute,
where accurate and detailed data on cancer types and age
of cancer diagnoses were available. The cancer registry has
a system of compulsory cancer registration since 1950.
Based on that information, probands were selected for
screening according to the liberal inclusion criteria
adapted from Brussels [12]: (i) probands with at least two
first degree relatives with breast and ovarian cancer; (ii)
probands with only two first degree relatives of breast can-
cer where one must be diagnosed less than 50 years of age;
and (iii) individual patients with breast and ovarian can-
cer, bilateral breast cancer, breast cancer diagnosed before
the age of 40 and male breast cancer without any other
cancer in the family.
The multidisciplinary team supervising the process of
counselling, screening and testing was composed of a sur-
gical oncologist, a medical oncologist, a molecular biolo-
gist, a radiation oncologist, a radiologist, a gynaecologist,
a geneticist, a cancer genetic counsellor and a research
nurse.
After a mutation was found in the proband, all possible
carriers in the family were offered, via the probands,
genetic counselling and genetic testing, each time covered
by an informed consent.
Mutation screening
The mutation screen was performed in the Laboratory of
Molecular Oncology at the Vrije Universiteit Brussel, on
leucocyte DNA obtained from blood samples using the
QIAamp DNA blood midi kit (Qiagen, Hilden, Ger-
many). The full open reading frame of both BRCA1 and
BRCA2 genes was analyzed in families with more than
one ovarian or breast cancer case, except in families with
only 2 breast cancer cases. In these families we restricted
the mutation screen for cost-effectiveness reasons to the
large exons of BRCA1/2 (by PTT) and the highly recurrent
mutations identified in the course of the study (BRCA1
exons 5 and 20, BRCA2 exon 17). A restricted mutation
analysis was also performed on isolated cases with bilat-
eral breast cancer, isolated male breast cancer cases and
isolated cases having developed breast and ovarian can-
cer.BMC Medical Genetics 2008, 9:83 http://www.biomedcentral.com/1471-2350/9/83
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The large exons (exon 11 from BRCA1, exons 10 and 11
from BRCA2) were analyzed by the Protein Truncation
Test [13]. All small coding exons as well as the ends of the
large exons were analyzed by Denaturing Gradient Gel
Electrophoresis (Ingeny International, Goes, The Nether-
lands) [14]. A multiplex Ligand probe assay (MLPA) for
the BRCA1 gene was performed with probe set P002 and
confirmed with probe set P087 (MRC-Holland, Amster-
dam, The Netherlands), each time on a batch of 8 sam-
ples. Data analysis (normalization and equalization) was
performed using a self designed Excel spreadsheet. Sam-
ples revealing abnormal migration profiles, suggestive for
the presence of a mutation were subjected to nucleotide
sequencing (Sequenase Version 2.0 DNA sequencing kit
from USB).
Statistical analysis
Descriptive statistics were used for analysis of the data.
Mean values and test for equality of means were calcu-
lated with the SPSS statistical software program.
Results
Four hundred thirty seven cancer patients received the ini-
tial inquiries and 289 returned them of which finally
probands from 150 (39%) different families matched the
inclusion criteria. Only 5 (3.3%) of these declined further
testing. A BRCA1/2 mutation screen was performed on
145 families and a cancer predisposing mutation was
found in 56 (39%). The mutations were distributed over
the whole length of the BRCA1  and  BRCA2  coding
sequences (Figure 1). After the cancer predisposing muta-
tion was identified in the family, 95 additional family
members from 36 of these families decided to have a test
of which 40 were identified as carriers.
BRCA1 mutation analysis
Thirteen distinct BRCA1 mutations were found in 38 fam-
ilies (Figure 1). Seven of the mutations were protein trun-
cating, 4 missense mutations and 2 genomic
rearrangements. The 4 different pathogenic missense
found in fourteen families were located in exon 3
(235G>A) and exon 5 (300T>G, 300T>A, 310G>A). These
mutations all affect one of the 7 RING domain cysteines
that are crucial for correct binding of the Zn atoms. Several
Identified BRCA1/2 mutations in Slovenian breast and/or ovarian cancer families Figure 1
Identified BRCA1/2 mutations in Slovenian breast and/or ovarian cancer families.
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mutations were found repeatedly in different families.
These include already reported 1806C>T BRCA1 mutation
[6] found in 10 families; and the 5382insC BRCA1 muta-
tion found in five families, which is the second most com-
mon reported mutation worldwide. The 967ins7 BRCA1
mutation was found three times. All other mutations,
including 2 novel large deletions in BRCA1, one involving
exons 5 to 8, the other exons 5 to 10, were detected only
once (Figure 1).
BRCA2 mutation analysis
Nine distinct BRCA2 mutations were identified in 18 fam-
ilies (Figure 1). Eight are protein truncating mutations,
while one was a splice site mutation, the IVS16-2A>G.
This mutation is often found in Slovenian breast cancer
families (10 families) and was already reported by our
group [10]. All other mutations found in BRCA2 gene
were detected only once (Figure 1).
Mutation detection rate
Although more families need to be investigated to reach
statistical significance, the probability of finding a muta-
tion correlated numerically with the number of affected
patients in breast cancer only families: with 3 or less
affected members mutations were found in 16/64 families
(25%) compared to 10/21 (48%) when there were more
than 3 affected family members.
However in families with ovarian cancer a mutation was
found in 24/46 (52%) of families with less than four
affected members and in 7/14 (50%) families with greater
than three affected family members, indicating that the
presence of ovarian cancer seems much stronger predictor
for finding a BRCA1/2  mutation than the number of
breast cancer cases in the family. The presence of recurrent
mutations in this population permits the identification of
cancer predisposing mutations in 67% of the BRCA1/2
mutant families by just analyzing 4 PCR fragments by
DGGE. A screen restricted to these 4 fragments could
therefore be performed on patients with a low probability
for finding a BRCA1/2 mutation.
Cancer phenotypes in families with a BRCA1 or BRCA2 
mutation and genotypic-phenotypic correlations
The sample size and mixed inclusion criteria does not per-
mit an accurate assessment of genotype-phenotype corre-
lations, however some trends could be observed.
The ages at diagnosis as well as the number and types of
cancer in each family with a mutation are shown in the
additional file 1. The mean age at breast cancer diagnosis
in BRCA1 mutation carriers was 42.98 years and 48.71
years for BRCA2 mutation carriers, respectively. By using T
test for equality of means, difference between mean age in
both groups at breast cancer diagnosis was statistically sig-
nificant (p = 0.038).
The most frequent cancers in BRCA1/2 positive families
are summarized in the table 1.
Ovarian cancers (OC) were more often found in BRCA1
families compared with BRCA2 families. Consequently, a
breast cancer only phenotype was found in a minority of
BRCA1 mutation families (14 out of 38), but a majority of
BRCA2 families (11 out of 18).
It is noteworthy that in our series the average number of
breast cancers (BC) per family was twice as much in
BRCA2  families (3.3) as compared to BRCA1  families
(1.6).
Because of the occurrence of a few highly recurrent muta-
tions, we had had the opportunity to estimate the relative
risk for breast versus ovarian cancer in these particular
families. In the 10 BRCA1  families with the 1806C>T
mutation we counted 23 cases of BC compared to 11 cases
of OC (relative risk: 2.1). For the 14 families with a mis-
sense mutation in the Ring-Finger domain the relative risk
was quite similar (3.4; 41 BC and 12 OC cases). In the 10
families with the BRCA2 splice site mutation IVS16-2A>G
the ratio of BC vs. OC was very high (49 BC and 3 OC; rel-
ative risk: 16.33). In our previous report we reported this
as a BC only mutation. With the expansion of families a
few OC were identified.
To get an estimate of the relative cancer penetrance among
the three types of families with a recurrent cancer predis-
posing mutations we determined how many female first
Table 1: Overall frequency of cancer types in 56 BRCA1/2 positive families
No. of affected family members BC bil BC MBC OC CC GC leukemia pro Ca pan Ca Ca uterus sarcoma
38 BRCA1 positive families 62 17 0 33 14 4 5 2 4 6 2
18 BRCA2 positive families 59 7 4 7 5 3 3 1 4 0 0
OC – ovarian cancer, BC – breast cancer (female), bil – bilateral, MBC – male breast cancer, CC – colon cancer, GC – gastric cancer, pan – 
pancreas, pro – prostate, Ca – cancer, Nr. – numberBMC Medical Genetics 2008, 9:83 http://www.biomedcentral.com/1471-2350/9/83
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degree relatives of the index case above 18 years devel-
oped breast cancer (see additional file 1). This breast can-
cer incidence is 17.8% (13/73) and 15.1% (8/53) in
BRCA1 families with a Ring domain missense mutation
and 1806C>T, respectively. In BRCA2 IVS16-2A>G fami-
lies we found a breast cancer incidence of 24.6% (15/61),
which is higher than what is seen in the two types of
BRCA1 families. The penetrance of ovarian cancer is much
lower in IVS16-2A>G BRCA2 families than in BRCA1 fam-
ilies with a Ring domain missense mutation or the
1806C>T mutation.
Discussion
Slovenia is a central European area country and despite a
complex history of occupation throughout history and the
fact that it has been an independent country for only 17
years, the population has preserved its own language and
culture for centuries. Currently 83% of the population is
considered of Slovene origin. Most Slovenes live in the
current Slovenia, but due to variations in the size of the
country significant Slovene populations also live in sur-
rounding countries especially Austria, northern Italy and
also some Balkan countries.
In this report we tested 145 breast and/or ovarian cancer
families in Slovenia for BRCA1/2 gene mutations.
There was a striking high interest for genetic testing after
providing systematic and standardized information using
written material. Only 5 probands (3.3%) from 150 fam-
ilies that met our inclusion criteria for screening refused
mutation analysis. This level of participation is considera-
bly higher than some report in the literature, where
around 50% of eligible probands opt for screening [15]. It
seems that the information about the screening was com-
municated on the adequate level of understanding. The
high participation rate of probands contrasted sharply
with the subsequent low interest in counselling of family
members. Only an average of two possible or probable
carriers per BRCA 1/2 mutation positive family came for-
ward spontaneously to request testing. The reasons for
this lack of interest are not known, as we did not investi-
gate this on our population. Adequate proband-based
information dissemination in a proband mediated model
was identified in Belgium by Sermijn et al. as highly
anomalous [16]. That study showed that in reality the
interest in counselling and testing was high as almost all
relatives wanted to be further informed about the various
aspects concerning hereditary breast/ovarian cancer and
also subsequently requested a genetic test after being
properly informed. This also agrees with our high partici-
pation rate observed in the properly informed probands.
Since we often face genetic counselling for members of
small families, we applied minimal selection criteria
before initiating a search for BRCA1/2 mutations. Despite
these liberal criteria the overall mutation detection rate
(MDR) was 39% (56/145 screened families), which is
high when compared to what was previously reported for
other populations where the MDR are between 15% and
37% with usually more stringent selection criteria with
regard to familial cancer phenotype than in our study [17-
21]. The intake criteria we employed thus seemed ade-
quate and practical for further use in our population [12].
It is also possible that with our mutation screening meth-
odology we did not detect all possible mutations and thus
we have a lower estimate of the mutation rate in our pop-
ulation. For the same reason the actual mutation hetero-
geneity could be greater than we estimate.
It is known and was also observed in the current series,
that the best MDR were obtained in families with either a
high number of breast cancer cases or families that also
include ovarian cancers, in which case the number of
breast cancers is of lesser importance. Such a high MDR of
> 50% in families that also include at least one ovarian
cancer case has also been observed in other populations
[12]. However, more Slovene breast cancer only families
were found mutation-positive as compared with compa-
rable Belgian families. Perhaps the high MDR in this type
of families can be explained by the occurrence of a highly
recurrent founder mutation in the Slovene families that
predispose almost exclusively and at high penetrance for
breast cancer (IVS16-2A>G in BRCA2) since ignoring the
families with this mutation leads to comparable MDR for
both populations.
We found 2 novel large deletions involving exons 5–8 and
5–10 of BRCA1 that probably occurred through a recom-
bination event between misaligned repetitive elements
(Alu repeats) abundant within the intron sequences of
BRCA1.
Four distinct types of mutations occurred very frequently
in the Slovene population. In fact, the analysis of only 4
PCR fragments (1806C>T, exon 5 (300T>G, 300T>A),
5382insC in the BRCA1  gene and IVS16-2A>G in the
BRCA2 gene) would lead to the identification of the can-
cer predisposing mutations in 67% of the BRCA1/2 muta-
tion-positive families. Therefore the genetic screening was
initiated with the detection of these four particular DNA
regions. As a result, families that do not strictly meet the
including criteria for the genetic screen can be submitted
to a restricted analysis when cost-effectiveness is an issue
and a mutation screen would otherwise not be engaged.
Earlier in the current project we discovered a Slovenian
founder mutation in three of the first seven screened fam-
ilies (BRCA2 splice site mutation IVS16-2A>G) [10]. This
mutation was found in the current series in 10/56 (18%)BMC Medical Genetics 2008, 9:83 http://www.biomedcentral.com/1471-2350/9/83
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of all families carrying a BRCA1/2  mutation and is
together with the world wide recurrent 1806C>T muta-
tion in BRCA1 gene the most common mutation in Slov-
enian population. According to the BIC database IVS16-
2A>G was reported worldwide only three times, twice by
Myriad in "Western Europeans" and once by Santarosa
from Aviano, an Italian city only 50 km from Slovenian
border [22,23].
The BRCA1 mutation 1806C>T was found in 10/56 BRCA
1/2 positive families (18%). This nonsense mutation clus-
ters mainly in Sweden, and is reported as a Swedish
founder mutation. The mutation however has also been
found in Belgian and Spanish families, and according to
the BIC database in German, Austrian, Dutch, Danish and
Italian ethnic populations as well [24-26].
We found an exceptionally high proportion (37%) of
pathogenic missense mutations in the RING Finger
domain. The RING motif is characterized by a conserved
pattern of 7 cysteine and 1 histidine residues arranged in
an interleaved fashion forming two distinct Zn2+ binding
sites termed Site I and Site II [27]. Interestingly, each of
the 3 cysteines involved in Site II is affected by one of the
4 identified missense mutations. One of these mutations,
300T>A, was found in 5 families and has not been
reported elsewhere. According to the data available in BIC
database and from the literature, such a high frequency
and clustering of RING Finger domain missense muta-
tions is reported Italy, our neighbouring country [6] and
in Czech Republic, Latvia, Poland, Hungary [28-31].
As the Slovene population mixed to some extent with the
inhabitants of neighbouring countries (Austria, Italy,
Hungary and Croatia) we can assume that we also share
some BRCA1/2 mutations with these populations. Indeed,
all three most common mutations found (except for the
Slovenian founder mutation) in Slovenians segregate in
Italian and Austrian families [6,32-34]. Unfortunately,
there is a lack of data on BRCA1/2 mutations from the
remainder of the Balkan region. There were only few
reports of BRCA1/2 mutation screening in the region of
former Yugoslavia [35] and by comparing results the only
common mutation found was BRCA1 5382insC, which is
known as an Ashkenazi Jewish mutation that occurs fre-
quently in the Central and Eastern Europe (Czech Repub-
lic, Lithuania, Poland, Slovakia, Russia) [28,30]. This
mutation accounts for 5/56 (9%) positive families in our
series.
With regard to familial cancer phenotype this relatively
small cohort does not allow for the uncovering of subtle
differences between the BRCA1/2 mutant families, except
for the double incidence rate of ovarian cancers in BRCA1
compared to BRCA2 positive families as reported widely
before. Families with inherited mutations in the BRCA2
gene give rise to a multi-site cancer phenotype, which
includes besides breast cancer (in females and males),
ovarian, colon, stomach, pancreatic, prostate and laryn-
geal cancer, as reported before [36]. In our sample uterine
cancer was related to the BRCA1  gene mutation. Both
BRCA1 and BRCA2 mutation positive families included
cases of leukemia that accounted for about 2 percent of
affected individuals. In one family with 5382insC BRCA1
gene mutation, 2 cases with sarcoma were reported. Inter-
pretation of these results and risk assessment for these
other cancers is difficult in the view of the low penetrance
for these other cancers.
It is known that the risk for ovarian cancer might vary
depending on the location of the mutation within the
BRCA1/2 coding sequence although this information is
generally not used in the counselling process and does not
appear in any national guidelines broadly used [37,38].
The high rate of specific recurrent mutations seen in the
Slovene population allowed us to assess the relative risk
for breast and ovarian cancer for these particular muta-
tions [39]. The missense mutations in the RING domain
and a protein truncating mutation in exon 11 (1806C>T),
all located in BRCA1, induce comparable relative risks for
breast versus ovarian cancer (3.4 and 2.1 respectively),
while the BRCA2  IVS16-2G>A mutation appears to be
highly predisposing for breast cancer compared to ovarian
cancer. However, due to the small sample size these
results should be confirmed in a larger sample set.
Conclusion
In summary, BRCA1/2 mutation testing and counselling
met with a high acceptance rate in Slovenia and with a
high interest level in probands.
A high mutation detection rate and the frequent occur-
rence of a limited array of recurring mutations allow a
simple and fast initial test for BRCA1/2 mutation screen-
ing in families with Slovenian ancestry.
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